Epigenetic regulation of NAFLD: A preclinical study

Background & objectives Non-alcoholic fatty liver disease (NAFLD) is considered as the most prevalent chronic metabolic disease, characterised by steatosis, inflammation, and metabolic dysfunctions with impaired functions of liver enzymes. The fat mass and obesity-associated gene (FTO) plays an important role in fat accumulation in hepatocytes. We investigated how FTO regulated the expression of its target genes via m6A modification leading to the pathophysiology of NAFLD. Methods A NAFLD mouse model was developed by feeding C57Bl/6 male mice on high-fat, high-carbohydrate (HFHC) diet supplemented with fructose and sucrose up to 24 wk. Changes in the liver histology were examined in serial sections by microscopy and immunohistochemistry, the serum parameters were monitored by bioanalyser and ELISA. Expression of hepatic murine FTO (mFTO) and metabolic gene transcripts were quantified by qPCR and mRNA sequencing. mFTO protein expression was analysed by immunohistochemistry and western blotting. Results The NAFLD mouse model developed steatosis, inflammation, and fibrosis at 19-24 wk, along with elevated liver enzyme levels, altered lipid profiles, and increased mFTO expression. Transcriptomic analysis identified differentially expressed genes and pathways associated with NAFLD progression. Pharmacological inhibition of mFTO by entacapone restored m6A marks on gene transcripts and reversed the NAFLD phenotype. Interpretation & conclusions Gene expression profiling identified key metabolic pathways and molecular targets associated with NAFLD progression. It underscored the role of mFTO in altering the m6A methylation landscape essential for establishing NAFLD and highlighted its therapeutic potential for NAFLD-associated morbidities.

• Publication year

  2025

• Venue

  The Indian journal of medical research

• Publication date

  2025-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.25259/ijmr_945_2025PMID 41296577PMCID 12744571
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The role of DGAT1 and DGAT2 in regulating tumor cell growth and their potential clinical implications

  2024cited by this paper
• Global prevalence of nonalcoholic fatty liver disease: an updated meta-analysis on 78 million population over 38 countries.

  2024cited by this paper
• N6-methyladenosine RNA modification in nonalcoholic fatty liver disease.

  2023cited by this paper
• Roles of RNA m6A modification in nonalcoholic fatty liver disease

  2023cited by this paper
• Mouse models of nonalcoholic fatty liver disease (NAFLD): pathomechanisms and pharmacotherapies

  2022cited by this paper
• Studies on the fat mass and obesity-associated (FTO) gene and its impact on obesity-associated diseases

  2022cited by this paper
• Dysregulated m6A Modification Promotes Lipogenesis and Development of Non-alcoholic Fatty Liver Disease and Hepatocellular Carcinoma.

  2022cited by this paper
• Genetic and Diet-Induced Animal Models for Non-Alcoholic Fatty Liver Disease (NAFLD) Research

  2022cited by this paper
• Fat mass and obesity–associated protein promotes liver steatosis by targeting PPARα

  2022cited by this paper
• PPARgamma in Metabolism, Immunity, and Cancer: Unified and Diverse Mechanisms of Action

  2021cited by this paper
• Phosphoenolpyruvate carboxykinase in cell metabolism: Roles and mechanisms beyond gluconeogenesis

  2021cited by this paper
• Mechanisms and disease consequences of nonalcoholic fatty liver disease.

  2021cited by this paper
• CD36 promotes de novo lipogenesis in hepatocytes through INSIG2-dependent SREBP1 processing

  2021cited by this paper
• Fatty Liver Disease: Diagnosis and Stratification.

  2021cited by this paper
• Diet-Induced Models of Non-Alcoholic Fatty Liver Disease: Food for Thought on Sugar, Fat, and Cholesterol

  2021cited by this paper
• Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis

  2020cited by this paper
• NAFLD 2020: The State of the Disease.

  2020cited by this paper
• A new definition for metabolic associated fatty liver disease: an international expert consensus statement.

  2020cited by this paper
• Ubiquitin ligase TRUSS augments the expression of interleukin-10 via proteasomal processing of NF-κB1/p105 to NF-κB/p50.

  2020cited by this paper
• Critical role of NFκB in the pathogenesis of non-alcoholic fatty liver disease: a widespread key regulator.

  2020cited by this paper
• Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention

  2020cited by this paper
• Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

  2019cited by this paper
• Identification of entacapone as a chemical inhibitor of FTO mediating metabolic regulation through FOXO1

  2019cited by this paper
• Unraveling the Regulation of Hepatic Gluconeogenesis

  2019cited by this paper
• FTO promotes SREBP1c maturation and enhances CIDEC transcription during lipid accumulation in HepG2 cells.

  2018cited by this paper
• Genetics and epigenetics of NAFLD and NASH: Clinical impact.

  2018cited by this paper
• TRRUST v2: an expanded reference database of human and mouse transcriptional regulatory interactions

  2017cited by this paper
• The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD).

  2016cited by this paper
• Hepatic expression of FTO and fatty acid metabolic genes changes in response to lipopolysaccharide with alterations in m6A modification of relevant mRNAs in the chicken

  2016cited by this paper
• FTO influences adipogenesis by regulating mitotic clonal expansion

  2015cited by this paper
• The Obesity-Associated FTO Gene Encodes a 2-Oxoglutarate-Dependent Nucleic Acid Demethylase

  2007cited by this paper
• Design and validation of a histological scoring system for nonalcoholic fatty liver disease

  2005cited by this paper
• The forkhead transcription factor Foxo1 regulates adipocyte differentiation.

  2003cited by this paper
• Sterol carrier protein 2 and fatty acid-binding protein. Separate and distinct physiological functions.

  1985cited by this paper

• No citing papers are available for this paper.